Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285

Ads

You May Also Like

Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors

MADISON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical ...

ContraFect to Present at 10th Annual Biotech Showcase

YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

Immunicum AB (publ) Announces Upcoming Investor Events in October and November

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October ...